Abstract 861P
Background
Clinical Practice Guidelines (CPG) are developed to define the standard of care based on evidence-based data of highest quality and well defined procedures. Implementation of CPG into daily practice depends on CPG features and external factors and is the final step of a process which starts with dissemination and clinician’s knowledge. To evaluate the implementation of the CCR of the ESMO-ESGO-ESTRO CC on EC of 2014 the 3 societies conducted a survey based on clinical case histories.
Methods
A Working Group with one representative by society prepared 3 clinical case histories, one by society. Each case contained 5 questions, each with 5 possible answers, only one correct according to CCR and adequate to the clinical situation. Each society sent the survey to most of its members; answers were collected via SurveyMonkey platform in the ESMO website’s dedicated page. Heterogeneity (H) of answers was calculated with a Q statistics and quantified with I2 statistics, an estimate of the between groups variability with I2 values >50% representing substantial-considerable H.
Results
The survey was kept open from 07 to 10/2019. A total of 586 replies (54% from ESGO, 30% from ESMO and 16% from ESTRO) were received; 69% of ESGO responders were gynaecological oncologists, 74% of ESMO medical oncologists, 86% of ESTRO radiation oncologists specialized in gynaecological cancers. Table: 861P
| Clinical scenario | 1st case ESMO early stage | 2nd case ESGO high grade serous | 3rd case ESTRO stage III |
| >50% H | 3/5 questions | 3/5 questions | 4/5 questions |
| Overall mean % correct answers (range) | 26.4% - 75% | 16.2% - 44% | 13.6% - 51% |
| ESMO mean % correct answers (range) | 23% - 60.4% | 17.5% - 38.4% | 16.9% - 44% |
The percentage (%) of non-responders increased from the second case up to 48%.
Conclusions
Notwithstanding the limited sample size and the high % of non-responders, the survey showed a limited implementation of the CCR. Potential causes could be the low grade of evidence of some CCR, the availability of different options in the same CCR, the lack of regular updates, the rarity of some clinical situations. The need of a multidisciplinary approach in CPG and clinical management of EC is reinforced.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristiana Sessa.
Funding
Has not received any funding.
Disclosure
C. Sessa: Research grant/Funding (institution), Clinical study grant: AstraZeneca AG; Advisory/Consultancy: Basilea Pharmaceutica Ltd. N. Colombo: Advisory/Consultancy: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Tesaro/GSK; Advisory/Consultancy: Clovis; Advisory/Consultancy: Advaxis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda; Advisory/Consultancy: Immunogen; Advisory/Consultancy: Biocad; Non-remunerated activity/ies: ACTO onlus. All other authors have declared no conflicts of interest.